Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Director Molly Harper Sells 17,500 Shares of Stock

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Director Molly Harper sold 17,500 shares of the firm’s stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $22.00, for a total value of $385,000.00. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

Catalyst Pharmaceuticals Price Performance

Shares of NASDAQ CPRX opened at $22.07 on Friday. The company has a market cap of $2.63 billion, a price-to-earnings ratio of 18.70, a price-to-earnings-growth ratio of 3.44 and a beta of 0.75. The stock’s 50-day moving average is $21.26 and its two-hundred day moving average is $18.76. Catalyst Pharmaceuticals, Inc. has a 1-year low of $13.00 and a 1-year high of $24.27.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on CPRX shares. Stephens started coverage on shares of Catalyst Pharmaceuticals in a research report on Monday, November 18th. They set an “overweight” rating and a $35.00 price target for the company. StockNews.com raised Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 9th. Truist Financial upped their price target on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a “buy” rating in a research note on Monday, November 11th. Citigroup boosted their price objective on Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the company a “buy” rating in a report on Friday, August 9th. Finally, HC Wainwright restated a “buy” rating and set a $30.00 target price on shares of Catalyst Pharmaceuticals in a report on Friday, November 8th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $31.14.

Institutional Trading of Catalyst Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its position in shares of Catalyst Pharmaceuticals by 12.1% in the 1st quarter. Vanguard Group Inc. now owns 7,980,661 shares of the biopharmaceutical company’s stock valued at $127,212,000 after purchasing an additional 860,244 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Catalyst Pharmaceuticals by 9.6% during the second quarter. Dimensional Fund Advisors LP now owns 3,000,756 shares of the biopharmaceutical company’s stock worth $46,479,000 after purchasing an additional 263,099 shares in the last quarter. Pacer Advisors Inc. grew its stake in shares of Catalyst Pharmaceuticals by 130,918.8% during the second quarter. Pacer Advisors Inc. now owns 2,967,575 shares of the biopharmaceutical company’s stock worth $45,968,000 after purchasing an additional 2,965,310 shares in the last quarter. Renaissance Technologies LLC increased its holdings in Catalyst Pharmaceuticals by 15.2% in the second quarter. Renaissance Technologies LLC now owns 2,175,727 shares of the biopharmaceutical company’s stock valued at $33,702,000 after buying an additional 287,300 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD raised its position in shares of Catalyst Pharmaceuticals by 1.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,219,418 shares of the biopharmaceutical company’s stock worth $19,439,000 after acquiring an additional 22,860 shares in the last quarter. Institutional investors and hedge funds own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.